一分钟看懂
这是一项关于Esophageal Squamous Cell Carcinoma的II 期研究，登记的药物或干预包括Sacituzumab Tirumotecan (SKB264) plus Tislelizumab，当前状态为招募中。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sacituzumab Tirumotecan (SKB264) plus Tislelizumab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Shanghai Chest Hospital · 上海
公开的入选条件
- 1. Have voluntarily signed a written informed consent form (ICF) prior to the initiation of any study-specific procedures.
- 2. Be aged ≥18 years, regardless of sex.
- 3. Have histologically or pathologically confirmed esophageal squamous cell carcinoma (ESCC) that is assessed as unsuitable for definitive treatment modalities (including definitive chemoradiotherapy and/or surgery) according to the American Joint Committee on
- 4. Have previously received first-line systemic therapy consisting of an immune checkpoint inhibitor in combination with chemotherapy and have experienced radiographically confirmed disease progression during or after such treatment.
- 5. Have at least one measurable lesion as defined by RECIST version 1.1, as assessed by the investigator, which has not been previously treated with radiotherapy.
- 6. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- 7. Have a life expectancy of at least 12 weeks.
- 8. Have adequate organ and bone marrow function, without receiving blood transfusion, recombinant human thrombopoietin, or colony-stimulating factor treatment within 2 weeks prior to the first dose, as defined by all of the following laboratory criteria:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07811752；登记信息更新于 2026-09-10。